Odyssey Therapeutics, Inc. (ODTX) Stock Price & Analysis
Odyssey Therapeutics, Inc. (ODTX) closed at USD 19.54 on Wednesday, October 28, 2026, up 0.21% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 19.5; the Oct 28, 2026 session ranged USD 19.19–20.07 on volume of 210,309 shares. Market capitalization is $939.06M, with a 52-week range of USD 15.1–29.05 (NCM). Source: Nexqual, retrieved October 28, 2026 at 21:06 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ODTX.md
Key facts (ODTX)
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $32K; 1 not under a Rule 10b5-1 plan ($32K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $30.1M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 35.33 (range 27–44).
- Total return with dividends: 1Y +19.0% vs S&P 500 +13.6%; 5Y +19.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.93, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ODTX)
P/S 326.4x · P/B 2.2x · FCF yield -15.94% · Earnings yield -18.18%
Insider sales (SEC Form 4, open-market, last ~7 months) (ODTX)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Sr One Capital Management, Llc | 1,780 | $32K | 0% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (ODTX)
4 purchases, $30.1M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-11 | Sr One Capital Management, Llc | 555,555 | $10.0M | 18 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-08 | Dimension Capital Ii, L.P. | Director | 1,111,111 | $20.0M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Leiden Jeffrey M | Director | 5,000 | $100K | 20 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Haas Jason | Chief Financial Officer | 1,000 | $20K | 20 | Too little history (no open-market trades in 2023–2025) |
Analysts (ODTX)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 35.33 (low 27, high 44).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Buy | $27 |
| 2026-10-09 | Raymond James | Initiated | Outperform | $42 |
| 2026-08-27 | HC Wainwright & Co. | Initiated | Buy | $44 |
| 2026-08-07 | JP Morgan | Target raised | Overweight | $26 → $29 |
Total return (dividends reinvested) (ODTX)
| 1Y (from 2026-05-08) | 5Y (from 2026-05-04) | |
|---|---|---|
| Total return | +19.0% | +19.0% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 71.1% | 69.3% |
| Max drawdown | -42.3% (Sep 2026→Oct 2026) | -40.3% (Aug 2026→Oct 2026) |
ODTX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.27 | −$0.85 | Miss −49.4% | — |
| — | Quarter ended Mar 31, 2026 | −$6.75 | −$1.28 | Miss −427.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ODTX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 20, 2026 | 8-K | Regulation FD disclosure |
| Sep 9, 2026 | 8-K | Regulation FD disclosure |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ODTX company outlook (results filed Aug 4, 2026)
- “Additional details on both studies are expected to be shared in the second half of 2026.”
- “Second Quarter 2026 Financial Results As of June 30, 2026, Odyssey had cash, cash equivalents and marketable securities of $433.1 million, which are expected to fund Odyssey's operations into the second half of 2028.”
Quoted word-for-word from the SEC 8-K results press release.
ODTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.93 | $-0.89 | −$0.04 | $0 | 3 |
| Next quarter (ends Dec 2026) | $-1.01 | $-0.98 | −$0.03 | $0 | 3 |
| Current fiscal year (ends Dec 2026) | $-4.11 | $-4.22 | +$0.11 | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-4.36 | $-3.88 | −$0.48 | $0 | 3 |
Key Statistics (as of October 28, 2026 at 21:06 UTC)
| Price | USD 19.54 |
|---|---|
| Change | ▲ 0.21% (up) |
| Previous Close | USD 19.5 |
| Open | USD 19.33 |
| Day Range | USD 19.19 – 20.07 |
| 52-Week Range | USD 15.1 – 29.05 |
| Volume | 210,309 shares |
| Market Cap | $939.06M |
| Exchange | NCM |
Technical Analysis (ODTX)
Nexqual's technical model rates ODTX "SELL" based on 2 bullish and 4 bearish signals across 120 daily candles, as of October 28, 2026 at 21:06 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.45 (neutral) |
| vs SMA50 | Below (USD 21.98) |
| MACD | -0.58 (negative) |
Analyst Ratings (ODTX)
Wall Street analysts rate ODTX "Buy" based on 8 analysts, with a mean price target of USD 35.33 (range USD 27–44), per Nexqual as of October 28, 2026 at 21:06 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 35.33 |
| High Target | USD 44 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (ODTX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.93 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.27 vs est -0.85 ▼ miss |
| 2026-03-31 | USD -6.75 vs est -1.28 ▼ miss |
Source: Nexqual, October 28, 2026 at 21:06 UTC.
Financials & Fundamentals (ODTX)
| Total Revenue | $99,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -156392.92% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.06 |
| Current Ratio | 11.36 |
| Total Cash | $310.58M |
| Total Debt | $24.82M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$149.72M (-5203.9% of revenue) |
Source: Nexqual, October 28, 2026 at 21:06 UTC.
Financial Health Score (ODTX)
Nexqual rates Odyssey Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 21:06 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $311M cash vs $25M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$150M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -41%, ROA -35.3% (last 4 quarters, SEC) |
Ownership (ODTX)
| Insider Ownership | +6.19% |
|---|---|
| Institutional Ownership | +83.31% |
| Shares Outstanding | 48.06M |
| Float | 23.66M |
| Short % of Float | +7.79% |
Source: Nexqual, October 28, 2026 at 21:06 UTC.
Leadership (ODTX)
Odyssey Therapeutics, Inc. is led by Gary D. Glick, Founder, President, CEO & Director, per Nexqual as of October 28, 2026 at 21:06 UTC.
| Founder, President, CEO & Director | Gary D. Glick |
|---|---|
| Chief Financial Officer | Jason Haas |
| Senior Vice President of Strategy & Business Development | Collin Todd |
Major Backers & Investors (ODTX)
Notable institutional backers of Odyssey Therapeutics, Inc. include FMR, LLC, SR One Capital Management, LP, TPG GP A, LLC, according to Nexqual as of October 28, 2026 at 21:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 10.78% |
| SR One Capital Management, LP | 7.9% |
| TPG GP A, LLC | 7.68% |
| Lightspeed Management Company, L.L.C. | 7.51% |
| Orbimed Advisors LLC. | 6.24% |
| Fidelity | 4.2% |
| Sanofi | 4.14% |
| Deerfield Management Company, L.P | 2.18% |
Source: Nexqual, October 28, 2026 at 21:06 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:06 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt